(Q37537363)

20 August 2017

1 reference

title

How would I manage a sample submitted for flow cytometry analysis for suspicious chronic lymphocytic leukaemia (English)

1 reference

20 August 2017

0 references

1 reference

1 reference

3

Valter Gattei

1 reference

20 August 2017

Pietro Bulian

1

1 reference

20 August 2017

Giovanni Del Poeta

series ordinal

2

1 reference

20 August 2017

publication date

1 December 2009

1 reference

20 August 2017

published in

Hematological Oncology

1 reference

20 August 2017

volume

27

1 reference

20 August 2017

issue

4

1 reference

20 August 2017

page(s)

186-189

1 reference

2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia.

20 August 2017

cites work

1 reference

Chronic lymphocytic leukemia

21 January 2018

1 reference

7 January 2021

Revised guideline on immunophenotyping in acute leukaemias and chronic lymphoproliferative disorders

1 reference

7 January 2021

Flow cytometric immunophenotyping for hematologic neoplasms

1 reference

7 January 2021

Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone

1 reference

7 January 2021

Differential diagnosis in chronic lymphocytic leukaemia

1 reference

7 January 2021

CD5- B-cell lymphoproliferative disorders presenting in blood and bone marrow. A clinicopathologic study of 40 patients

1 reference

7 January 2021

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

7 January 2021

Prognostic markers in chronic lymphocytic leukaemia

1 reference

7 January 2021

Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia

1 reference

7 January 2021

Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia

1 reference

7 January 2021

CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential

1 reference

7 January 2021

CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia.

1 reference

7 January 2021

Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression

1 reference

7 January 2021

ZAP-70 expression in B-cell chronic lymphocytic leukemia: Evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgVH mutations

1 reference

7 January 2021

Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia

1 reference

7 January 2021

CD49d expression in chronic lymphocytic leukemia: a prognostic parameter and a therapeutic target

1 reference

7 January 2021

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

1 reference

7 January 2021

Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication

1 reference

7 January 2021

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

1 reference

7 January 2021

Identifiers

DOI

10.1002/HON.900

1 reference

20 August 2017

1 reference